Pere B. S.
- Country
- Spain
- Department
- Hematology Service
Research Overview
- Blinatumomab and Combination Therapy Versus Standard of Care in Older Adults With Newly Diagnosed Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia
- Randomized Precision Medicine Trial of Venetoclax Combination Therapy in Relapsed/Refractory T‑Cell Acute Lymphoblastic Leukemia
- Evaluation of Safety and Efficacy of AUTO1 CAR T Cells Targeting CD19 in Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Data & Insights
Has run more than one trial at 104 of 233 partner sites.
Specializations
Lymphoma Research
The investigator specializes in treating various forms of B-cell Non-Hodgkin Lymphoma, with particular emphasis on Large B-Cell Lymphoma (LBCL) and aggressive lymphoid malignancies.
- High-risk LBCL treatment
- Diffuse large B-cell lymphoma
- Relapsed/refractory B-cell lymphomas
Their work includes evaluating novel therapeutic approaches for both newly diagnosed and treatment-resistant cases.
Leukemia Studies
Focus areas include B-cell Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, with particular attention to challenging cases and innovative treatment strategies.
- Philadelphia Chromosome-Positive ALL
- Relapsed/refractory B-ALL
- Refractory AML treatments
The investigator explores targeted therapies and immunological approaches for these conditions.
Specialized Therapeutic Areas
Research extends to Epstein-Barr Virus-associated diseases and post-transplant complications, including various forms of lymphoproliferative disorders.
- EBV+ sarcomas
- Post-transplant lymphoproliferative disease
- Immunodeficiency-related conditions
The work encompasses both solid organ and hematopoietic cell transplant-related complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.